Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Y-mAbs Therapeutics, Inc. - Common Stock (NQ:YMAB)

4.530 +0.060 (+1.34%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Y-mAbs Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BioLineRx, Enovix, Southwest Airlines, and Y-mAbs and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
TOP RANKED ROSEN LAW FIRM Encourages Y-mAbs Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - YMAB
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Y-mAbs Therapeutics, Inc. (YMAB) Investor Alert: Robbins LLP Reminds Shareholders of Class Action Against Y-mAbs Therapeutics, Inc.
From Robbins LLP
Via Business Wire
The Latest Analyst Ratings for Y-mAbs Therapeutics
 
Via Benzinga
Analyst Ratings for Y-mAbs Therapeutics
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 27, 2023
 
Via Benzinga
YMAB NOTICE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Y-mAbs Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - YMAB
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Y-mAbs Therapeutics, Inc. (YMAB)
From Glancy Prongay & Murray LLP
Via Business Wire
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Y-mAbs Therapeutics, Inc. (YMAB)
From Law Offices of Howard G. Smith
Via Business Wire
How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
Five biotechs have already issued layoffs in 2023. Many seem to have good potential, but time will tell if the shifts create the value analysts anticipate. 
Via MarketBeat
Topics Workforce
Y-MABS THERAPEUTICS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess Of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Y-mAbs Therapeutics, Inc. - YMAB
From Kahn Swick & Foti, LLC
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Y-mAbs Therapeutics, Inc. (YMAB) Investors
From Glancy Prongay & Murray LLP
Via Business Wire
NOTICE: Investors in Y-mAbs Therapeutics, Inc. with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – YMAB
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BioLineRx, Enovix, Southwest Airlines, and Y-mAbs and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Y-mAbs Therapeutics (YMAB) Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Y-mAbs Therapeutics, Inc. (YMAB) Investors
From Law Offices of Howard G. Smith
Via Business Wire
ROSEN, A TOP RANKED LAW FIRM, Encourages Y-mAbs Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - YMAB
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Y-mAbs Therapeutics, Inc. (YMAB)
From Robbins LLP
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Y-mAbs Therapeutics, Inc. (YMAB) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
Y-MABS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Y-mAbs Therapeutics, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Y-mAbs Therapeutics, Inc. (YMAB) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Y-mAbs Therapeutics, Inc. (YMAB) Investors
From Kirby McInerney LLP
Via Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Y-mAbs Therapeutics, Inc. (YMAB) on Behalf of Investors
From Law Offices of Frank R. Cruz
Via Business Wire
INVESTOR NOTICE: Y-mAbs Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead the Y-mAbs Class Action Lawsuit - YMAB
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
EQUITY ALERT: Rosen Law Firm Encourages Y-mAbs Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – YMAB
From The Rosen Law Firm, P.A.
Via Business Wire
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Y-mAbs Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Y-mAbs Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
Y-mAbs Therapeutics Plans To Deprioritize Omburtamab For Pediatric Cancer, Cuts One Third Of Workforce
 
Via Benzinga
NASDAQ:YMAB Investor Alert: Investigation over Possible Securities Laws Violations by Y-mAbs Therapeutics, Inc
San Diego, CA -- (SBWIRE) -- 11/18/2022 -- Y-mAbs Therapeutics, Inc. is under investigation over potential securities laws violations in connection with certain financial statements. 
Via SBWire
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback